Comparative Pharmacology
Head-to-head clinical analysis: FEMLYV versus PHILITH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FEMLYV versus PHILITH.
FEMLYV vs PHILITH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of levonorgestrel, a progestin, and ethinyl estradiol, an estrogen; suppresses gonadotropins, inhibits ovulation, alters cervical mucus and endometrium.
PHILITH is a combined oral contraceptive containing ethinyl estradiol and drospirenone. Ethinyl estradiol suppresses gonadotropin release, while drospirenone is a progestin with antiandrogenic and antimineralocorticoid activity, inhibiting ovulation and altering cervical mucus.
FEMLYV (norethindrone acetate/ethinyl estradiol) is administered as one tablet (1 mg norethindrone acetate/20 mcg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo tablets. The dosing regimen is continuous cyclic.
1 mg orally once daily
None Documented
None Documented
Terminal elimination half-life is approximately 24-30 hours, supporting once-daily dosing in most patients.
Terminal half-life 12 hours; clinically relevant for twice-daily dosing with steady state reached after 2-3 days.
Primarily renal (approximately 60-70% as metabolites, less than 10% as unchanged drug); fecal excretion accounts for about 20-30%.
Renal: 90% unchanged; biliary/fecal: 10% as metabolites.
Category C
Category C
Oral Contraceptive
Oral Contraceptive